anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To dispose of used aerosol spray cans, with different levels of contents remaining in them, the can is passed into a zone where the pressure is below the ambient atmospheric pressure. The spray can (1) is opened from the bottom, and the remaining contents are allowed to emerge. The interior of the spray can (1) is washed and the empty and cleaned can is passed out of the underpressure zone thro9ugh a lock. The removed can contents, from the underpressure zone, are separated from the mixture of gas, solvent and contents material. Also claimed is an assembly with a closable converter (4) where the spray cans (1) are passed through a lock (2) into it. A holder clamps the can (1) while the bottom is opened. A vacuum pump maintains an underpressure within the converter (4). The contents of the cans, released in the underpressure zone, are sprayed with a solvent. The spraying and washing out of the cans is with recovered solvent. A following gas dome (14), with a vacuum pump to maintain an underpressure, separates the extracted fluid matter taken from the underpressure zone into volatile and fluid components. USE/ADVANTAGE - The system is for the disposal of discarded aerosol spray cans, which can still contain a level of unused contents of various types of material. The operation neutralises the cans, to prevent explosion or other effects in normal rubbish disposal and incineration, with recovery of the can contents, without damage to the environment.
PURPOSE:The titled cosmetic, obtained by dispersing crushed fragments of a metallized foil coated with a transparent resin layer uniformly in a solid oily material, liquid oily material, organic modified montmorillonite clay and perfume, and having improved storage stability and beautifying effect. CONSTITUTION:A makeup cosmetic for earlobes obtained by incorporating crushed fragments of a metallized foil, e.g. 5-50wt% gold, silver, Al, Cu or Ni, coated with a colorless or colored transparent resin layer on one or both sides thereof, with a solid oily material, e.g. 10-60wt% carnauba wax or beeswax, liquid oily material, e.g. 10-60wt% liquid paraffin or squalane, organic-modified montmorillonite clay, e.g. 0.1-3.0wt% benton, and a perfume (5-30wt%). EFFECT:Capable of exhibiting improved storage stability, heat resistance and perfume fixative property, good removal, extensibility, adhesiveness and feeling in use and good fragrance and makeup effect.
Primary immunodeficiency disease (PID) is a group of rare and fatal disease. However, the research about clinical characteristics, treatment, management and prognosis of Chinese children with PID is still not perfect and there is no basic and large database. Therefore, this study is conducted, in order to set up a complete database and long term follow up of Chinese children with PID, and establish foundations for basic research and precise medicine.

This study is divided into two parts. In part one, pediatric patients with PID in the past 10 years will be collected retrospectively by review medical records from these centers, and investigate the clinical features and prognosis. In part two, all new cases with suspected PID will be collected. Clinical symptoms, physical examination, blood tests, and humoral and cellular immune functions will be detected. Gene tests would be done when necessary to confirm the diagnosis. Then follow up at 6-moth, 1-year, 2-year, 3-year, 4-year and 5-year respectively. The trial will be completed in 60 months.
Cushing's disease (CD) is a disorder of chronic glucocorticoid (GC) excess that gives rise to a constellation of metabolic comorbidities and to a distinct lipodystrophic body habitus characterized by central adiposity, extremity wasting, and the accumulation of supraclavicular (SC) and dorsocervical (DC) fat in the region where human brown and beige adipose tissue is known to be concentrated. In spite of the recognized thermogenic capacity of select cervical adipocytes, the potential impact of lipomatous alterations in this depot on energy balance and metabolism in CD is unknown. To our knowledge, the "buffalo hump" and the supraclavicular fat pads - which are a sensitive physical finding for CD, have never been phenotypically characterized and the mechanisms underlying the GC mediated development of fat in these depots and the associated metabolic complications have not been explored in humans. The proposed research will advance our understanding of Cushing's lipodystrophy and its metabolic complications. Furthermore, it may lead to the identification of novel mediators and targetable pathways to attenuate the adverse effects of hypercortisolism on body composition and metabolism in CD, as well as in the significant population of patients treated with chronic GCs for an array of other clinical conditions. These findings may have important implications not only for those with Cushing's disease, but for the millions of Americans who are treated with chronic glucocorticoids for an array of clinical conditions.
Secondary objectives include the evaluation of short-term pain (Day 0 to Day 7), chronicisation of pain at 3 months, patient satisfaction regarding perioperative management and tolerance in both groups.

This is a monocentric, prospective, randomized, single-blind study. 80 adult patients, eligible for outpatient surgery under under WALANT for hand surgery such as carpal tunnel, stub finger, Dupuytren's disease or elbow surgery such as ulnar nerve compression and lacertus fibrosus syndrome, will be recruited during their care in the orthopedic and trauma surgery department at Nîmes University Hospital over an estimated period of 12 months. After receiving information, the intervention visit will be planned within 21 days. After collecting consent and checking the selection criteria, patients will be randomized (1:1 stratified according to hand/elbow surgery) for a procedure under WALANT anesthesia with 10 to 20 ml of 1% lidocaine (10 mg/mL) (depending on the procedure) combined with adrenaline (0.005mg/ml) with or without the addition of 15mg ropivacaine. An evaluation of the pain via a visual analog scale (0 to 10) will be carried out before discharge from the service and by telephone on Day 1 according to the current care then at Days 2 and 3 and 7 for the research. The patients will also have to answer questionnaires on their perioperative management (Evaluation of the experience of local anaesthesia or EVAN-LR) before leaving the department and then on the postoperative experience (Quality of Recovery or QoR-40) at D2 and the possible "chronicisation" of pain at 3 months (neuropathic pain or DN4) by telephone. Possible adverse events will be collected up to D7.
FIELD: medicine.SUBSTANCE: elastic venous compression orthosis intended for wearing in contact with a patient's skin is equipped with a device for measuring time, during which an orthosis is worn. Said device comprises a capacitive sensor which is adjustable to transmit a detection signal when the capacitance sensor capacitance value is within the operating range, and other sensor for detection and elimination of erroneous data from capacitive sensor. Kit for adhering to a treatment regimen under conditions wherein a patient wears an elastic venous compression orthesis comprising the above elastic venous compression orthesis and an external module, in particular a computer and/or a mobile telephone and/or a tablet. Said external module comprises a computer program including program code instructions for establishing communication, preferably remote communication, with communication module of measuring device and/or connection and/or disconnection of measuring device, and/or control of information exchange and, in particular, loading of information stored in memory device of measuring device. Method for improving observance of a treatment regimen based on the use of an elastic venous compression orthesis, and/or improving the performance of the elastic venous compression orthesis, wherein said method comprises the following sequential steps of providing the patient with said elastic venous compression orthesis, comprising a measuring device, loading data stored in a measuring device, preferably a computer, or a mobile phone or a tablet, preferably after the treatment period of more than one week, more preferably more than one month, or even more than three months, and analyzing the data to prepare a compliance assessment, and preferably a correlation between adherence to the treatment regimen, the orthesis characteristics and the therapeutic effect of the orthosis. Device for measuring time, during which an elastic venous compression orthesis is worn, comprises a capacitive sensor, controlled for transmission of detection signal only when capacity value of capacitance sensor is in operating range. Working range comprises, and preferably includes possible values of capacity during operation of orthesis, and other sensor for detection and exclusion of erroneous data from capacitance sensor.EFFECT: inventions provide the possibility of improved observance of the treatment regimen and obtaining data on the conditions under which the patient wears the orthosis.12 cl, 2 dwg
In order to investigate the impact of laparoscopic stripping surgery on follicular ovarian reserve, blood samples will be obtained before the operation, from 2nd to 5th day of the menstrual cycle, to determine levels of endocrine markers of ovarian reserve (FSH, E2, AMH and Inhibin B). Cancer antigen 125 (CA -125) and IL-6 will be measured also. US markers (antral follicular count- AFC) will be obtained at the same time as endocrine markers. All laparoscopic stripping surgery will be performed during the early or middle follicular phases of menstrual cycle, under general anesthesia, by the same team of gynecological endoscopist. The cyst wall will be completely stripped off from the normal ovarian tissue by traction and opposite traction with two grasping forceps. Hemostasis will be achieved using bipolar forceps electrocoagulation. All endometrioma specimens that will be obtained from operation will be submitted for pathology examination. One and six months after the laparoscopic cystectomy, from 2nd to 5th day of menstrual cycle, we will determine endocrine markers of ovarian reserve and levels of CA 125 and IL-6.

The control group will be consisted of healthy women with infertility problem. From the second to the fifth day of the menstrual cycle we will take blood samples to determinate endocrine markers of follicular ovarian reserve: AMH, FSH, E2, Inhibin B.
Children and adolescent from 10 to 18 years old, with a history of type 1 diabetes for at least 10 years. Glomerular hyper filtration and endothelial dysfunction will be evaluate.
Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet and will receive 2 capsules which100 grams of standardized oleuropein-containing olive leaf extract.
The invention discloses application of A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments. The compounds have the following general formula I, and comprise Ia, Ib, Ic, Id, Ie and If. The growth inhibition rate of the A-nor-5 alpha-androstane compounds for in-vitro human liver cancer cell Hep 3B, human breast cancer MDA-MB-231, human lung adenocarcinoma A549 and mouse melanoma B16 is higher than 85% on average, and even up to 99.98% to the maximum. The in-vivo test proves that the inhibition rate of the A-nor-5 alpha-androstane compounds for mouse tumors, such as intestinal cancer C26, liver cancer H22, Lewis lung cancer, breast cancer, B16 melanoma and the like, is higher than 50% on average, and even up to 63.19% to the maximum. The result proves that the compounds disclosed by the invention have an obvious malignant tumor resistant action. The A-nor-5 alpha-androstane compounds disclosed by the invention have an obvious and broad-spectrum action on inhibiting growth of malignant tumor cells, and are novel targeted malignant tumor resistant medicaments with low drug toxicity and favorable treatment effect; and the A-nor-5 alpha-androstane compounds just specifically act on tumor cells, but not influence normal cells, thereby having a high clinical application value.
The invention relates to an external aerosol for curing a cold. An appropriate amount of antiviral, antiallergic and antipyretic analgesic injection is added into medical ethanol to prepare mixed solution. The mixed solution is filled in an aerosol generating device container. When the aerosol is used, aerial fog is generated near nostrils on both sides, and then the user closes mouth to inspire air and opens mouth to expire air. The ethanol and the antiviral ingredients can kill pathogenic microorganism at a focus position and prevents the pathogenic microorganism parasitizing mucosa of the nasal cavity and the surface of the secretion thereof from repeatedly invading and the antiallergic and antipyretic analgesic medical ingredients in the aerosol can carry out symptomatic treatment so as to fulfill the aim of curing the cold. The external aerosol has the advantages of good effect, short treatment period, reduction in complications and prevention of side effect of an oral medicament for curing the cold.
Participants will receive TMC278 25 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
Lateral ankle sprains (LASs) are common injuries in sports and physical activities, with up to 40% of individuals experiencing a first-time LAS developing chronic ankle instability (CAI). LASs predominantly affect the anterior talofibular ligament, and residual symptoms can persist in a significant percentage of patients. However, many individuals with ankle sprains do not seek professional treatment, leading to potential underestimation of the injury severity. CAI is characterized by recurrent episodes of ankle giving way, ongoing symptoms, reduced ankle range of motion, diminished self-reported function, and persistent ankle sprains beyond one year. It is attributed to both mechanical and functional instability, with factors such as proprioceptive deficits and mechanical insufficiencies contributing to the condition. Taping, particularly rigid taping, is commonly used by athletes to enhance joint stability and improve dynamic balance and functional performance. Rigid taping limits joint movement, improves joint position, and provides external support without compromising functional performance. Taping is especially prevalent in multidirectional sports like basketball, where ankle sprains are frequent. The use of tapes aims to restrict ankle movement, increase joint stability, and enhance proprioception without hindering athletic performance.
Adult patients(18-50 years old) ASA I-II without sepsis submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
A pet care device includes a server, a pet wearable unit and a pet dormitory. The pet wearable unit includes a physiological detection module and a non-contact sensing module. The physiological detection module detects the pet's physiological information, and the non-contact sensing module has pet serial number information. The pet dormitory includes dormitory body, access control lock, dormitory camera module, and image judgment module. The access control lock is connected to the non-contact sensor module, and when the pet serial number information matches the preset serial number information, it obtains the physiological information and opens the dormitory body, and drives the dormitory camera module located in the pet dormitory to capture images in the dormitory. The image judgment module judges the image in the dormitory and drives the access lock to close the dormitory body according to the judgment result.
PURPOSE:To obtain a solid drug for oral administration having shielded disagreeable taste in high efficiency, by adding an organic solvent to a powdery mixture of a drug and a substance capable of shielding disagreeable taste, granulating the product and removing the solvent from the granule. CONSTITUTION:A powdery drug having disagreeable taste (e.g. an antiepileptic such as zonisamide or a macrolide antibiotic substance such as erythromycin, etc.) is mixed with a powdery substance capable of shielding disagreeable taste (usually a polymeric compound hardly soluble or insoluble in water and saliva). The mixture is added with an organic solvent which dissolves the powdery substance and preferably does not dissolve the drug (e.g. ethanol, chloroform, acetone, etc.) and granulated. The organic solvent is removed after granulation. The powdery substance is preferably finer than 100 mesh, especially 200 mesh and the amount of the substance in the final product is <=50wt.%, preferably 3-20wt.%.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to surgical dentistry. Remote root fragment with a preserved portion of the connective ligament of the tooth is used to close the hole with orienting the surface of the removed root with the ligamentous apparatus towards the alveolar opening. It is followed with reduction and reconstruction of the replanted root under the dimensions of the gingival contour of the tooth socket with preserving the residual dental bond on the side surface of the replanted root and on the surface facing the opening of the socket. Prepared replant is immersed throughout depth of residual ligamentous apparatus of lateral surface in gingival contour of alveoli. At that, immersion of the replant into the gingival part of the socket of the removed tooth is performed after the hole full filling with a blood clot. That is followed by temporarily fixing a fragment of the replanted root covering the hole of the socket, using a suture material, a filling composite material or a combination of the above methods to adjacent teeth. Fragment of the repaired root is removed at least 2.5 months after tooth extraction.EFFECT: method provides easier healing of the hole after tooth extraction, eliminated development of alveolitis, avoided atrophy of alveolar bone in first 3 months after tooth extraction without using special osteoplastic materials, can be applied to any tooth in dental row.1 cl, 2 ex, 20 dwg
Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.
INTRODUCTION: Bronchiectasis is a worldwide chronic lung disorder where exacerbations are common. It affects people of all ages, but especially Indigenous populations in high-income nations. Despite being a major contributor to chronic lung disease, there are no licensed therapies for bronchiectasis and there remain relatively few randomised controlled trials (RCTs) conducted in children and adults. Our RCT will address some of these unmet needs by evaluating whether the novel mucoactive agent, erdosteine, has a therapeutic role in children and adults with bronchiectasis.Our primary aim is to determine in children and adults aged 2-49 years with bronchiectasis whether regular erdosteine over a 12-month period reduces acute respiratory exacerbations compared with placebo. Our primary hypothesis is that people with bronchiectasis who regularly use erdosteine will have fewer exacerbations than those receiving placebo.Our secondary aims are to determine the effect of the trial medications on quality of life (QoL) and other clinical outcomes (exacerbation duration, time-to-next exacerbation, hospitalisations, lung function, adverse events). We will also assess the cost-effectiveness of the intervention.
METHODS AND ANALYSIS: We are undertaking an international multicentre, double-blind, placebo-RCT to evaluate whether 12 months of erdosteine is beneficial for children and adults with bronchiectasis. We will recruit 194 children and adults with bronchiectasis to a parallel, superiority RCT at eight sites across Australia, Malaysia and Philippines. Our primary endpoint is the rate of exacerbations over 12 months. Our main secondary outcomes are QoL, exacerbation duration, time-to-next exacerbation, hospitalisations and lung function.
ETHICS AND DISSEMINATION: The Human Research Ethics Committees (HREC) of Children's Health Queensland (for all Australian sites), University of Malaya Medical Centre (Malaysia) and St. Luke's Medical Centre (Philippines) approved the study. We will publish the results and share the outcomes with the academic and medical community, funding and relevant patient organisations.
TRIAL REGISTRATION NUMBER: ACTRN12621000315819.
The present invention provides the process of preparing the topical anti-inflammatory and analgesic preparation comprising herbal ingredients. The process involves the extraction of herbal ingredients in the solvent; concentrating; filtration of solvent; addition of base oil; removel of solvent by boiling the mixture; resultant extract is allowed to cool; and addition of volatile oils. The process for preparation of compositions comprises of the extratction of invidual herb or a mixture thereof. Cissus quadragularis (Asthisamhara) and Costus specious (Bramhatirtha) are the essential herbs to provide synergistic compositions. The other herbal ingredients used optionally in the process are Terminalia chebula (Haritaki), Terminali bellerica (Bibhitaka), Emblica officinalis (Amalaki), Melia azadirchta (Nimba), Vitex negundo (Nirgundi), Commiphora mukul (Guggulu). The volatile oils used optinally in the process are Pinus longifolia (Sarala), Camphora officinarum (karpur), Apium graveolens (Ajmoda), Cedrus deodara (Devdaru oil), Eucalyptus globulus (Nilgiri oil), Melaleuca leucadendron (cajuput oil). The compositions derived from the process are found to be effective in relieving various painful and inflammatory conditions.
Severe cutaneous reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. DRESS may present with a cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis. These events can be fatal. Patients with a prior history of Grade 4 rash associated with thalidomide treatment should not receive lenalidomide. Consider lenalidomide interruption or discontinuation for Grade 2-3 skin rash. Permanently discontinue lenalidomide for Grade 4 rash, exfoliative or bullous rash, or for other severe cutaneous reactions such as SJS, TEN or DRESS [see Dosage and Administration (2.5)].